Clinical Trials Logo
  1. Home
  2. Bladder Cancer
  3. NCT05643690
  4. Details
NCT05643690 Clinical Trial

Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay

Bladder Cancer Clinical Trial

Official title:
Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay in Subjects Suspected of Having Bladder Cancer

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT05643690
Other study ID # UriFind US-001
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date November 18, 2022
Est. completion date April 18, 2024

Study information
Verified date April 2024
Source PPsanalytics
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The AnchorDx UriFind™ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer. Results from the assay are intended for use, in conjunction with current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients.

Recruitment information / eligibility
Status Terminated
Enrollment 77
Est. completion date April 18, 2024
Est. primary completion date April 9, 2024
Accepts healthy volunteers No
Gender All
Age group 55 Years to 100 Years
Eligibility Inclusion Criteria: Clinical Validation Group: 1. 55 years or older, gender is not limited 2. Suspected of bladder cancer and are scheduled for bladder biopsy or trans-uretheral resection of bladder tumor (TUBRT) 3. Can receive standard of care, including urine cytology, cystoscopy, or surgery for bladder cancer diagnosis 4. Can provide at least of 75 ml of urine (prior to cystoscopy or surgery) Exclusion Criteria: 1. History of urinary cancer 2. Neoadjuvant therapy

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• UriFind Bladder Cancer Assay
The AnchorDx UriFind™ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer. Results from the Assay are intended for use, in conjunction with current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients.

Locations
Country Name City State
United States Arkansas Urology Little Rock Arkansas
United States Idaho Urologic Institute Meridian Idaho

Sponsors (3)
Lead Sponsor Collaborator
PPsanalytics AnchorDx Medical Co., Ltd., Specialty Networks

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Sensitivity and Specificity of UriFind assay in detecting early stage Bladder Cancer To evaluate the performance of the UriFind assay relative to the patient at diagnosis (cystoscopy or surgery followed by histology). Baseline
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06034015 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers Phase 1
Recruiting NCT04235764 - En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Completed NCT02371447 - VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT04081246 - Transurethral Modified En Bloc Resection For Large Bladder Tumours. N/A
Recruiting NCT06059547 - Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer Phase 2
Terminated NCT04779489 - Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer N/A
Not yet recruiting NCT04493489 - Propranolol Adjuvant Treatment of Bladder Cancer Phase 2
Completed NCT03520231 - Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Phase 2
Recruiting NCT04537221 - Nordic Cystectomy Study III - Transfusion
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT01955408 - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment N/A
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05562791 - A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer Phase 1
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT02781428 - To Detect the Sensitivity of the UroMark Assay
Recruiting NCT04738630 - Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Phase 2
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03978624 - Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Phase 2
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A